| 2019 | Radiomics on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma
| CLINICAL CANCER RESEARCH |
| 2021 | Radiomics With Ensemble Machine Learning Predicts Dopamine Agonist Response in Patients With Prolactinoma | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM |
| 2009 | Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2009 | Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2015 | Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience
| RADIATION ONCOLOGY JOURNAL |
| 2012 | Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors | ANNALS OF HEMATOLOGY |
| 2013 | Radiotherapy Prolongs Biliary Metal Stent Patency in Malignant Pancreatobiliary Obstructions
| GUT AND LIVER |
| 2018 | Radon Exposure-induced Genetic Variations in Lung Cancers among Never Smokers
| JOURNAL OF KOREAN MEDICAL SCIENCE |
| 2011 | RAGE and cardiovascular disease | FRONTIERS IN BIOSCIENCE |
| 2010 | RAGE ligands induce apoptotic cell death of pancreatic β-cells via oxidative stress | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
| 2009 | RAGE signaling in inflammation and arterial aging
| FRONTIERS IN BIOSCIENCE |
| 2015 | RAGE siRNA-mediated gene silencing provides cardioprotection against ventricular arrhythmias in acute ischemia and reperfusion | JOURNAL OF CONTROLLED RELEASE |
| 2022 | Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis | CALCIFIED TISSUE INTERNATIONAL |
| 2020 | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
| CANCER RESEARCH AND TREATMENT |
| 2017 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study | EUROPEAN JOURNAL OF CANCER |
| 2017 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score | JAMA ONCOLOGY |
| 2014 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | LANCET |
| 2014 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | LANCET |
| 2022 | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) | GASTRIC CANCER |
| 2021 | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
